data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzdoNTEydjM0MS4zMjZIMHoiLz48cGF0aCBmaWxsPSIjRkY5ODExIiBkPSJNMCA4NS4zMzdoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjNkRBNTQ0IiBkPSJNMCAzMTIuODg4aDUxMnYxMTMuNzc1SDB6Ii8+PGNpcmNsZSBmaWxsPSIjMDA1MkI0IiBjeD0iMjU2IiBjeT0iMjU2IiByPSI0My44OTYiLz48Y2lyY2xlIGZpbGw9IiNGRkYiIGN4PSIyNTYiIGN5PSIyNTYiIHI9IjI3LjQzNCIvPjxwYXRoIGZpbGw9IiMwMDUyQjQiIGQ9Ik0yNTYgMjIyLjE0Nmw4LjQ2NCAxOS4xOTUgMjAuODU1LTIuMjY4TDI3Mi45MjcgMjU2bDEyLjM5MiAxNi45MjctMjAuODU1LTIuMjY4TDI1NiAyODkuODU0bC04LjQ2NC0xOS4xOTUtMjAuODU1IDIuMjY4TDIzOS4wNzMgMjU2bC0xMi4zOTItMTYuOTI3IDIwLjg1NSAyLjI2OHoiLz48L3N2Zz4=

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Yield
How to Buy Corporate Bonds
How to Buy Treasury Bonds
How to Invest in Real Estate Online
Money
Compare Online Brokers
Stock Brokers
Forex Brokers
Futures Brokers
Crypto Brokers
Options Brokers
ETF Brokers
Mutual Fund Brokers
Index Fund Brokers
Bond Brokers
Short Selling Brokers
Stock Apps
All Broker Reviews
Insurance
Auto
Home
Medicare
Life
Vision
Dental
Business
Pet
Health
Motorcycle
Renters
Workers Comp
Top Stocks
Penny Stocks
Stocks Under $5
Stocks Under $10
Stocks Under $20
Stocks Under $50
Stocks Under $100
Alternative Investing
Invest in Art
Invest in Watches
Invest in Land
Invest in Real Estate
Invest in Wine
Invest in Gold
Mortgages
Refinance
Purchase
Find a Mortgage Broker
Alts
Alternative Investment Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
How to Invest in Jewelry
Best Real Estate Crowdfunding Platforms
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Get Started
Is Bitcoin a Good Investment?
Is Ethereum a Good Investment?
What is Blockchain
Best Altcoins
How to Buy Cryptocurrency?
DeFi
Crypto and DeFi 101
What is DeFi?
Decentralized Exchanges
Best DeFi Yield Farms
Digital Securities
NFTs
NFT Release Calendar
What is a Non-Fungible Token (NFT)?
How to Buy Non-Fungible Tokens (NFTs)
CryptoPunks Watchlist
Are NFTs a Scam or a Digital Bubble?
Best In Crypto
Best Crypto Apps
Best Crypto Portfolio Trackers
Best Crypto Day Trading Strategies
Best Crypto IRA
Best Cryptocurrency Scanners
Best Business Crypto Accounts
Best Crypto Screeners
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Halozyme Therapeutics Inc

(NASDAQ:HALO)

GET A REPORT ON HALO SENT RIGHT TO YOUR INBOX

EMAIL*

Perks Buy Compare Brokers

$39.95

-0.20[-0.50%]

Last update: 4:20PM (Delayed 15-Minutes)
Get Real Time Here

$39.95

0[0.00%]

After-Hours

Perks Buy Compare Brokers

Open40.020	Close39.950
Vol / Avg.732.927K / 901.497K	Mkt Cap5.277B
Day Range39.470 - 41.064	52 Wk Range29.850 - 59.390

0

Latest News for Halozyme Therapeutics Stock (NASDAQ:HALO)

Halozyme Therapeutics Stock (NASDAQ: HALO)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Thursday, November 16, 2023

Halozyme Announces argenx Receives European Commission Approval of VYVGART SC With ENHANZE For Generalized Myasthenia Gravis
Benzinga Newsdesk - Nov 16, 2023, 9:05AM

Monday, November 06, 2023

Halozyme Raises 2023 Adj. EPS Guidance To $2.70-$2.80 vs $2.65 Est.
Benzinga Newsdesk - Nov 6, 2023, 4:44PM
Halozyme Therapeutics Q3 2023 Adj EPS $0.75 Beats $0.73 Estimate, Sales $216.03M Miss $222.63M Estimate
Benzinga Newsdesk - Nov 6, 2023, 4:31PM
Earnings Scheduled For November 6, 2023
Benzinga Insights - Nov 6, 2023, 8:24AM
Acumen Pharmaceuticals, Inc. And Halozyme Enter Global Collaboration And License Agreement To Develop Subcutaneous Formulation Of ACU193 With ENHANZE Technology
Benzinga Newsdesk - Nov 6, 2023, 7:31AM

Friday, November 03, 2023

Earnings Outlook For Halozyme Therapeutics
Benzinga Insights - Nov 3, 2023, 11:01AM

Friday, October 20, 2023

Benchmark Reiterates Buy on Halozyme Therapeutics, Maintains $50 Price Target
Benzinga Newsdesk - Oct 20, 2023, 10:28AM

Thursday, October 19, 2023

Opdivo's Subcutaneous Formulation Shows Promise in Advanced Kidney Cancer: Bristol Myers Squibb's Latest Findings
Vandana Singh - Oct 19, 2023, 10:25AM
Halozyme Therapeutics Highlights Bristol Myers Squibb Phase 3 CheckMate-67T Trial Results Of Subcutaneous Nivolumab With Halozyme's ENHANZE Drug Delivery Technology For Advanced Or Metastatic Clear Cell Renal Cell Carcinoma
Bill Haddad - Oct 19, 2023, 7:19AM
Bristol Myers Squibb's Phase 3 Checkmate -67T Noninferiority Trial Of Subcutaneous Opdivo (Nivolumab) Compared To Intravenous Opdivo For Clear Cell Renal Cell Carcinoma Met Its Co-primary Pharmacokinetics Endpoints, Key Secondary Endpoint
Benzinga Newsdesk - Oct 19, 2023, 7:07AM
HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $61
Benzinga Newsdesk - Oct 19, 2023, 6:54AM

Monday, October 09, 2023

Analyst Expectations for Halozyme Therapeutics's Future
Benzinga Insights - Oct 9, 2023, 3:00PM
HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $60 Price Target
Benzinga Newsdesk - Oct 9, 2023, 6:17AM

Friday, September 08, 2023

Where Halozyme Therapeutics Stands With Analysts
Benzinga Insights - Sep 8, 2023, 9:00AM
HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $60 Price Target
Benzinga Newsdesk - Sep 8, 2023, 7:06AM

Thursday, September 07, 2023

Halozyme Therapeutics Says Was Informed by License Partner Roche That There Will Be A Delay In Projected Launch Timing For Tecentriq SC With ENHANZE In The US
Benzinga Newsdesk - Sep 7, 2023, 7:19AM

Wednesday, August 30, 2023

HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $60 Price Target
Benzinga Newsdesk - Aug 30, 2023, 6:08AM

Tuesday, August 29, 2023

Halozyme Wins Approval for Roche's Tecentriq Subcutaneous (SC) with ENHANZE in Great Britain
Benzinga Newsdesk - Aug 29, 2023, 4:53AM

Tuesday, August 15, 2023

Expert Ratings for Halozyme Therapeutics
Benzinga Insights - Aug 15, 2023, 8:00AM
HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Lowers Price Target to $60
Benzinga Newsdesk - Aug 15, 2023, 7:13AM

Thursday, August 10, 2023

Morgan Stanley Maintains Overweight on Halozyme Therapeutics, Raises Price Target to $61
Benzinga Newsdesk - Aug 10, 2023, 10:29AM

Tuesday, August 08, 2023

Halozyme Therapeutics Sees FY23 EPS $2.65-$2.75 VS $2.61 Est; Revenue $825M-$845M Vs $823.06M Est
Benzinga Newsdesk - Aug 8, 2023, 4:33PM
Halozyme Therapeutics Q2 EPS $0.74 Beats $0.63 Estimate, Sales $221.00M Beat $199.32M Estimate
Benzinga Newsdesk - Aug 8, 2023, 4:03PM
Earnings Scheduled For August 8, 2023
Benzinga Insights - Aug 8, 2023, 4:48AM

Friday, July 28, 2023

Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations
Vandana Singh - Jul 28, 2023, 1:47PM

Monday, July 24, 2023

Halozyme's Subcutaneous Drug Delivery: Analysts Initiate With 'Buy' Rating, Say Enhanze Tech Targets $41.7B Market
Vandana Singh - Jul 24, 2023, 2:36PM
Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023
Benzinga Insights - Jul 24, 2023, 11:00AM
HC Wainwright & Co. Initiates Coverage On Halozyme Therapeutics with Buy Rating, Announces Price Target of $61
Benzinga Newsdesk - Jul 24, 2023, 6:42AM
Goldman Sachs Downgrades Halozyme Therapeutics to Neutral, Raises Price Target to $45
Benzinga Newsdesk - Jul 24, 2023, 4:49AM

Monday, July 17, 2023

Halozyme Therapeutics shares are trading higher after the company reported topline data from the ADHERE study evaluating VYVGART Hytrulo with ENHANZE in adults with chronic inflammatory demyelinating polyneuropathhy.
Benzinga Newsdesk - Jul 17, 2023, 12:38PM
Reported Early July 17, Halozyme Therapeutics, Inc. Reports Topline Data From Argenx's ADHERE Study Of VYVGART Hytrulo With Halozyme's ENHANZE Drug Delivery Technology In Patients With Chronic Inflammatory Demyelinating Polyneuropathy
Happy Mohamed - Jul 17, 2023, 12:37PM

Thursday, July 13, 2023

Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion
Vandana Singh - Jul 13, 2023, 9:22AM
Roche's OCREVUS With Halozyme's ENHANZE Drug Delivery Technology Announced Results From Phase 3 OCARINA II Trial In Patients With Multiple Sclerosis
Benzinga Newsdesk - Jul 13, 2023, 2:04AM

Wednesday, June 21, 2023

Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis
Vandana Singh - Jun 21, 2023, 9:56AM
The FDA Approved Argenx's Vyvgart Hytrulo (Efgartigimod Alfa And Hyaluronidase-qvfc) For Generalized Myasthenia Gravis, It Utilizes Halozyme's ENHANZE Drug Delivery Technology
Benzinga Newsdesk - Jun 21, 2023, 4:02AM

Tuesday, June 20, 2023

10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights - Jun 20, 2023, 1:39PM

Wednesday, May 31, 2023

AI Frenzy Helps Nasdaq 100 Outshine Russell 2,000 And Soar To Dot-Com Bubble Highs
Piero Cingari - May 31, 2023, 10:38AM

Wednesday, May 10, 2023

Halozyme shares are trading higher after the company reported Q1 results. Piper Sandler upgraded the stock to Overweight following the report.
Benzinga Newsdesk - May 10, 2023, 11:38AM
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023
Benzinga Insights - May 10, 2023, 11:00AM
JMP Securities Reiterates Market Outperform on Halozyme Therapeutics, Maintains $66 Price Target
Benzinga Newsdesk - May 10, 2023, 8:41AM
Morgan Stanley Maintains Overweight on Halozyme Therapeutics, Lowers Price Target to $60
Benzinga Newsdesk - May 10, 2023, 8:01AM
Piper Sandler Upgrades Halozyme Therapeutics to Overweight, Announces $46 Price Target
Benzinga Newsdesk - May 10, 2023, 5:40AM

Tuesday, May 09, 2023

Halozyme Therapeutics: Q1 Earnings Insights
Benzinga Insights - May 9, 2023, 5:06PM
Halozyme Therapeutics Reiterates 2023 Revenue Guidance Of $815-$845M, Representing 23-28% Y/Y Growth; Consensus $833M
Benzinga Newsdesk - May 9, 2023, 4:50PM
Halozyme Therapeutics Q1 Adj EPS $0.47 Misses $0.48 Estimate, Sales $162.10M Miss $175.51M Estimate
Benzinga Newsdesk - May 9, 2023, 4:04PM
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - May 9, 2023, 1:25PM
Earnings Scheduled For May 9, 2023
Benzinga Insights - May 9, 2023, 6:03AM

Monday, May 08, 2023

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - May 8, 2023, 1:49PM
Halozyme Therapeutics Earnings Preview
Benzinga Insights - May 8, 2023, 10:02AM

Friday, May 05, 2023

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - May 5, 2023, 1:54PM

1
2
3
4
5
6
7
Next
17

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2023 Benzinga | All Rights Reserved